论文部分内容阅读
目的:探究不同剂量尿激酶联合低分子肝素钙治疗急性心肌梗死的临床效果。方法:以我院收治的急性心肌梗死患者250例为研究对象,随机分为观察组和对照组,观察和对比两组的临床治疗效果。结果:观察组患者的血管再通率为78.4%,显著高于对照组患者的血管再通率63.2%,观察组患者的出血并发症发生概率为4.0%,显著低于对照组的17.6%,两组数据差异具有统计学意义(P<0.05)。结论:采用较小剂量的尿激酶联合低分子肝素钙治疗急性心肌梗死的临床效果更佳,且安全性较高,具有临床应用和推广的价值。
Objective: To investigate the clinical effects of different doses of urokinase combined with low molecular weight heparin on acute myocardial infarction. Methods: A total of 250 acute myocardial infarction patients treated in our hospital were randomly divided into observation group and control group. The clinical effects of the two groups were observed and compared. Results: The recanalization rate of the observation group was 78.4%, significantly higher than that of the control group 63.2%. The incidence of bleeding complications in the observation group was 4.0%, significantly lower than that of the control group 17.6% The difference between the two groups was statistically significant (P <0.05). Conclusion: A lower dose of urokinase combined with low molecular weight heparin calcium is more effective and safe in the treatment of acute myocardial infarction. It has the value of clinical application and promotion.